Dr. Thai Ho has been caring for patients affected by genitourinary cancers for over 10 years. His area of expertise and the focus of his research is in treating kidney and bladder cancers. He also sees patients with kidney, bladder, upper tract urothelial, and prostate cancers, as well as patients affected by hereditary cancer syndromes. Dr. Ho completed the Baylor College of Medicine Physician Scientist Program in 2006, internal medicine residency at Washington University in St. Louis in 2009, and Medical Oncology Fellowship at MD Anderson Cancer Center in 2012.Dr. Ho's research is funded by the National Institutes of Health and Department of Defense to better match cancer patients with targeted therapies by using precision medicine approaches to identify a cancer's unique vulnerabilities. At MUSC Hollings Cancer Center, Dr. Ho is the Director of Precision Medicine and an Associate Professor in the Division of Hematology \& Oncology. Prior to joining MUSC, Dr. Ho was an Associate Professor faculty the Mayo Clinic where he was a member of the Center for Individualized Medicine Epigenomics Group, Genomic Tumor Board, and von Hippel-Lindau Clinic.

Dr. Ho is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Nephrectomy, and Orchiectomy.

He is actively involved in clinical research, co-authoring 100 peer reviewed articles and participating in 7 clinical trials.

Graduate Institution

Baylor College Of Medicine Physician Scientist Program, 2006

Residency

Washington University: Internal Medicine

Specialties

Hematology Oncology

Oncology

Licenses

Internal Medicine in MO

Fellowships

MD Anderson Cancer Center: Medical Oncology, 2012

Hospital Affiliations

Musc Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina

HMO
MANAGED MEDICAID PLAN
MEDICARE-MEDICAID PLAN

Aetna

Blue Cross Blue Shield

Cigna

Clover Health

INSURANCE PLAN
MEDICARE MAPD

First Health

INSURANCE PLAN
MEDICARE PDP
PPO

Humana

HMO
INDEMNITY
POS
PPO

UnitedHealthcare

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 4 Less Insurance Carriers -

Locations

MUSC Health Hematology Oncology at Hollings Cancer Center
86 Jonathan Lucas St, 2nd Floor, 3rd Floor, Charleston, SC 29425

Call: 843-792-9300

Additional Areas of Focus

Dr. Ho has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Penile Cancer

Prostate Cancer

Bladder Cancer

Testicular Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

Enrollment Status: Recruiting

Publish Date: April 16, 2026

Intervention Type: Procedure, Biological, Drug

Study Drugs: Cabozantinib, Ipilimumab, Nivolumab

Study Phase: Phase 2

Phase II Study of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma